JP2020527044A - ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法 - Google Patents

ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法 Download PDF

Info

Publication number
JP2020527044A
JP2020527044A JP2020501456A JP2020501456A JP2020527044A JP 2020527044 A JP2020527044 A JP 2020527044A JP 2020501456 A JP2020501456 A JP 2020501456A JP 2020501456 A JP2020501456 A JP 2020501456A JP 2020527044 A JP2020527044 A JP 2020527044A
Authority
JP
Japan
Prior art keywords
treg
days
population
cells
cd45rc low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020501456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527044A5 (https=
Inventor
ギロンノー，キャロル
アネゴン，イグナシオ
ベジエ，セヴェリーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2020527044A publication Critical patent/JP2020527044A/ja
Publication of JP2020527044A5 publication Critical patent/JP2020527044A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020501456A 2017-07-13 2018-07-12 ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法 Pending JP2020527044A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305939.5 2017-07-13
EP17305939 2017-07-13
PCT/EP2018/068882 WO2019012024A1 (en) 2017-07-13 2018-07-12 METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / -

Publications (2)

Publication Number Publication Date
JP2020527044A true JP2020527044A (ja) 2020-09-03
JP2020527044A5 JP2020527044A5 (https=) 2021-08-12

Family

ID=59399380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020501456A Pending JP2020527044A (ja) 2017-07-13 2018-07-12 ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法

Country Status (4)

Country Link
US (1) US20210147801A1 (https=)
EP (1) EP3652306A1 (https=)
JP (1) JP2020527044A (https=)
WO (1) WO2019012024A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104411819B (zh) * 2012-06-11 2019-05-10 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
US20220168394A1 (en) * 2019-04-23 2022-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing or restoring immune tolerance
CA3172120A1 (en) * 2020-03-20 2021-09-23 Inserm (Institut De La Sante Et De La Recherche Medicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
WO2024028486A1 (en) * 2022-08-04 2024-02-08 Nantes Universite In vitro method for obtaining clinical-grade cd8+ cd45rclow/- regulatory t cells
IL322333A (en) * 2023-02-07 2025-09-01 Quell Therapeutics Ltd Culture method for TREG cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017005647A1 (en) * 2015-07-03 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for obtaining regulatory t cells and uses thereof
WO2017042170A1 (en) * 2015-09-07 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A new subpopulation of cd8+cd45rclow tregs and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US551413A (en) 1895-12-17 Willakd b
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US20030008923A1 (en) 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20130189282A1 (en) * 2010-07-23 2013-07-25 Indiana University Research And Technology Corpora Methods for isolating and using a subset of cd8 t-cells that are resistant to cyclosporin
WO2016009041A1 (en) * 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017005647A1 (en) * 2015-07-03 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for obtaining regulatory t cells and uses thereof
WO2017042170A1 (en) * 2015-09-07 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A new subpopulation of cd8+cd45rclow tregs and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEZIE, S., ET AL.: ""IL-34 is a Treg-specific cytokine and mediates transplant tolerance."", J. CLIN. INVEST., vol. 125, no. 10, JPN6022016452, 2015, pages 3952 - 3964, XP055249807, ISSN: 0004768314, DOI: 10.1172/JCI81227 *
FAN, H., ET AL.: ""Efficient Induction and Expansion Of CD8+CD28+Foxp3+ Regulatory T Cells By TGF-beta1 and Rapamycin.", BLOOD, vol. 122, no. 21, JPN6022016453, 15 November 2013 (2013-11-15), pages 190, XP086752048, ISSN: 0004768315, DOI: 10.1182/blood.V122.21.190.190 *

Also Published As

Publication number Publication date
US20210147801A1 (en) 2021-05-20
EP3652306A1 (en) 2020-05-20
WO2019012024A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US20230313136A1 (en) Abcb5 positive mesenchymal stem cells as immunomodulators
ES2589311T5 (es) Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos
ES2765884T3 (es) Métodos de expansión y evaluación de linfocitos B y uso de linfocitos B expandidos para el tratamiento de enfermedades
Sykes Immune tolerance: mechanisms and application in clinical transplantation
ES2769778T3 (es) Composiciones inmunomoduladoras
JP2020527044A (ja) ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法
JP2002506831A (ja) 移植で免疫応答の予防と処置のための間葉幹細胞を利用する方法とその組成物
CN108135935A (zh) 表达pd-l1的造血干细胞及其用途
JP6580791B2 (ja) 調節ｔ細胞媒介性疾患の予防または治療用薬学的組成物
Peters et al. Immunotherapy with regulatory T cells in transplantation
US20250017967A1 (en) Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
AU2013204421B2 (en) ABCB5 positive mesenchymal stem cells as immunomodulators
Lan et al. SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISM IMPAIRS SKIN DENDRITIC CELL MIGRATION AND HOMING TO SECONDARY LYMPHOID TISSUE: ASSOCIATION WITH PROLONGED ALLOGRAFT SURVIVAL.
Jinushi et al. Yuan Tan, Bodour AlKhamees, Deyong Jia, Li Li, Jean-François Couture, Daniel Figeys
HK1201295B (en) Abc5 positive mesenchymal stem cells as immunomodulators
HK1129703B (en) Abcb5 positive mesenchymal stem cells as immunomodulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221206